Harrison.ai vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
Harrison.ai is an Australian healthcare AI company building clinical-grade AI for radiology and pathology diagnostics; raised $129M+ AUD total at a $400M AUD valuation; its Annalise.ai radiology platform has FDA clearance and processes 5M+ studies;
About
Harrison.ai is a Sydney, Australia-based healthcare artificial intelligence company founded in 2018 by brothers Aengus and David Hallinan that builds clinical-grade AI models for diagnostic medicine, initially targeting radiology and pathology. The company''s flagship product — Annalise.ai — is a comprehensive AI platform for radiology interpretation that analyzes chest X-rays, CT scans, and other medical imaging studies to detect and flag a broad range of findings simultaneously. Unlike earlier radiology AI tools designed for single conditions, Annalise.ai is a multi-finding model trained to detect up to 124 findings in a single chest X-ray and 295 findings in chest CTs — providing a comprehensive AI second reader experience rather than a narrow single-disease detector.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.